Free initial consultationPRC-licensed physiciansCold-chain delivery nationwide
lab63
Ask a doctor
Recovery · Rx onlyBPC—01

BPC157 & TB500

the repair stackBody Protection Compound + Thymosin Beta-4

A combined repair-peptide protocol for tissue, tendon, and joint recovery — dosed together and monitored by your physician through the full course.

Daily micro-dose8–12 week courseReview wk 4 · 8Physician-supervised
Check your eligibilityRead the clinical reference →
The evidence2×

Two peptides, one protocol: BPC157 acts locally on tissue and tendon; TB500 supports cell migration and repair systemically. Evidence is preclinical and early-clinical — your physician will be direct about what is and isn’t established.

Candidacy

Who this is for

Adults recovering from soft-tissue injury, tendon strain, or repetitive training load — where a genuine recovery indication exists. Candidacy is decided by your physician against your history and imaging, never by a checkout flow.

Often appropriateTendon or ligament injury confirmed by exam or imagingPost-surgical recovery under specialist careRecurring training injuries with rehab already attempted
Not appropriateActive or recent malignancy — growth-factor signalling is contraindicatedPregnancy or breastfeedingUnexplained pain without diagnosis — investigate first, treat second
Runners in motion, long exposure
Back to trainingRecovery is the program. Training is the goal.
The program

How the program works

01
Day 0Free video consultation

A PRC-licensed physician reviews your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.

02
Week 1Baseline review & first dose

Baseline review of the injury — history, imaging if needed. Your pens ship cold-chain once your physician signs the prescription.

03
Weeks 2–8Daily dosing & check-ins

Both peptides dose daily by micro-injection. A video review at week 4, with messaging in between.

04
Week 8–12Full review

Function and pain reviewed against baseline. Together you decide: continue, taper, or return to full load.

Included

What’s included

Two single-patient pens, named prescriptioncGMP facility
Cold-chain delivery to your door1–2 days, Metro Manila
Injury baseline and progress reviewsweeks 4, 8
Video reviews through the coursenamed physician
Load management and rehab guidanceevery check-in

No prices on this site by design — your program is quoted in full after your consultation, before anything is dispensed.

Questions

Common questions

Most protocols run 8–12 weeks. Some patients report earlier changes in pain and mobility, but tissue remodelling is slow biology — your physician reviews function at weeks 4 and 8 rather than promising a date.

Find out if this fits youFree 20-min video consultation
Book

Often combined with

All →
MetabolicRetatrutidePhysician-managed weight therapy with structured check-ins.LongevityNAD+ 1000Cellular energy support alongside metabolic programs.
DiagnosticsBaseline longevity panelThe blood work every program starts from.
The science

Two peptides, two mechanisms

BPC-157 nitric oxide and FAK-paxillin

BPC-157 effects on tissue repair are characterised mechanistically via the nitric oxide system (Klicek et al, J Pharmacol Sci, 2008) and FAK-paxillin phosphorylation in tendon fibroblasts (Chang et al, J Appl Physiol, 2011). The two pathways converge on cell migration and survival.

TB-500 actin sequestration

Thymosin beta-4 is the principal actin-sequestering peptide in eukaryotic cells. It binds G-actin monomers and modulates F-actin polymerisation dynamics. The actin-binding activity underlies the cell migration and tissue-repair effects observed across the published TB-4 literature.

TB-500 epicardial progenitor mobilisation

Smart and colleagues (Nature, 2007;445(7124):177-182) reported that thymosin beta-4 induces adult epicardial progenitor mobilisation and neovascularisation. The progenitor-mobilisation property provides a candidate mechanism for tissue-repair effects across multiple organ systems.

Combination rationale

The combination of BPC-157 and TB-500 in research protocols rests on the complementarity of distinct mechanistic pathways (nitric oxide and FAK-paxillin from BPC-157; actin sequestration and progenitor mobilisation from TB-500). Combination effects have not been characterised in large peer-reviewed clinical trials; the combination is studied in research community protocols.

BPC157 & TB500 is also searched as Thymosin beta-4, Tβ4, BPC157 TB500.